摘要
胰腺癌在世界范围内呈增多趋势,已成为癌症致死第4位病因,胰腺癌5年生存率小于5%[1]有＂癌中之王＂之称,被国际医学界列为＂21世纪的顽固堡垒＂,其起病隐匿、病情进展快、恶性程度高.
出处
《中国医药导刊》
2010年第6期920-922,共3页
Chinese Journal of Medicinal Guide
参考文献14
-
1Han SS,Kim SW,Jang JY,et al.A comparison of the long-term functional outcomes of standard pancreatoduodenectomy and pylorus-preserving pancreatoduodenectomy[J].Hepatogastroen-terolo-gy,2007;54(78):1831-1835.
-
2Akizuki E,Kimura Y,Nobuoka T,et al.Prospective nonrandomized comparison between pylorus-preservingand subtotal stomach--preserving pancreaticoduodenectomy from the perspectives of DGE occurrence andpostoperative digestive functions[J].J Gastrointnst Surg,2008;12(7):1185-1192.
-
3Sa Cunha A,Rank A,Beau C,et al.A singleinstitution prospective study of laparoscopic pancreaticresection[J].Arch Surg,2008; 143(3):289-295.
-
4Puglies R,Scandroglio I,Sansonna F,et al.Laparoscopic pancrcaticoduodenectomy:a retrospective review of 19 cases[J].Surg Laparosc Endosc Percutan Tech,2008; 18(1):13-18.
-
5Berlin JD,Catalano P,Thomas JP,et al.Phase Ⅲstudy of gemeitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma:Eastern Cooperative Oncolog Y Group Trial E2297.J Clin Oncol,2002;20(15):3270-3275.
-
6Ferrari V,Valearnonico F,Arrloro,so Ⅳ,et al.Gemcitabine plua celecoxib (GECo)in Mvanced pancreatic cancer:a phase Ⅱ trial[J].Cancer Chemother Pharmacol,2006;57(2):185-190.
-
7Ikeda O,Kusunoki S,Kudoh K,et al.Evaluation of the efficacy of combinedcontintmus arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma[J].Cardiovase Intervcnt Radiol,2006;29(3):362-370.
-
8Ganta S,Amiji M.Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.Mol Pharm,2009May-Jun;6(3):928-939.
-
9Kim J,Czischke K,Brennan MF,et al.Dose neoadjuvant chemora.diation downstage locally advancd pancreatic cancer.J Gastrointest Surg,2002;6(5):763-769.
-
10Ammori JB,Colletti LM,Zalupski MM,et al.Surgicat resection following radiation therapy with concurent gemcitabine in patients withpreviously unresectable ad of the pancreas.J Gastrointest Surg,2003;7(6):766-772.
同被引文献52
-
1One-layer pancreaticojejunostomy for prevention of pancreatic fistulae[J].Hepatobiliary & Pancreatic Diseases International,2004,3(1):140-143. 被引量：2
-
2Mclaughlin R,Hanlon D,Kerin M,et al.Are elevated levels of the tumour marker CA19- 9 of any clinical significance-an evaluation[J].Ir J Med Sci,1999;168(2): 124-126.
-
3Simeone DM,Ji B,Banerjee M,et aI.CEACAMI,a novel serum biomarker for pancreatic cancer[J].Pancreas,2007:36:436-443.
-
4Obrink B.On the role of CEACAM1 in cancer[J].Lung Cancer,2008;60(3):309-312.
-
5Samsen A,Bogoevska V, Klampe B,et aI.DC-SIGN and SRCL bind glycans of carcinoembryonic antigen (CEA) and CEA-related cell adhesion molecule 1 (CEACAM1):recombinant human glycanbinding receptors as analytical tools[J]. Ettr J Cell Biol,2010;89(1):87-94.
-
6Chaturvedi P, Singh AP.Moniaux N,et aI.MUC4 potentiates pancreatic tumor cell proliferation,survival,and invasive properties and interikres with its interaction to extracellular matrix proteins[J].Mol Cancer Res,2007;5(4):309-320.
-
7Ji B,Tsou L,Wang H,et al.Rasactivity Levels control the development of pancreatic diseases[J].Gastr oenter ology,2009;137(1): 1072-1082.
-
8Ohuchida K,Mizumoto K,Yamada D,et al.Quantit ative analysis of human telomem sereverse Wanscriptase in pancreatic cancer[J].Clin Cancer Res,2006; 12( 1 ):2066-2069.
-
9Vincent A, Herman J, Schulick R,et al. Pancreatic cancer [J]. Lan-cet, 2011, 378(9791): 607-620.
-
10Du卸 A, Capanu M,Allen P, et al. O'Reilly EMPanereatic adenocar-'cinoma in a young patient population-12-year experience at Memori-al Sloan Kettering Cancer Center [J]. J Surg Oncol, 2009,100: 8-12.
引证文献3
-
1潘忠威,太京华,杨瑞,赵阳.多种肿瘤标志物诊断胰腺癌的临床价值[J].中国医药导刊,2012,14(11):1875-1875.
-
2张彤.影响胰十二指肠切除术后胰漏的因素分析[J].中国医药导刊,2014,16(3):448-449. 被引量：2
-
3韦君亮,赵铁军.胰腺导管腺癌早期临床诊断策略展望[J].海南医学,2014,25(10):1482-1484.
二级引证文献2
-
1孙建明,余华,刘明忠,王翔翔,赵宇,熊杰,陈磊.胰腺残端不同吻合术式对胰十二指肠切除术后胰漏的影响[J].疑难病杂志,2015,14(2):158-160. 被引量：8
-
2李天满,周任,庞志东.胰头癌可切除性评估研究进展[J].医学理论与实践,2016,29(17):3022-3024. 被引量：1
-
1张海荣,孟祥伟,徐光.胰腺癌的临床诊断进展[J].吉林医学,2007,28(13):1522-1524. 被引量：4
-
2赵玉沛,刘子文.现有诊断方法在胰腺癌早期诊断中价值的评估[J].外科理论与实践,2002,7(5):337-338. 被引量：6
-
3周道其.2017年能否攻克癌症堡垒[J].现代科技译丛（哈尔滨）,2000(4):26-27.
-
4孙建平.中药在胰腺癌临床治疗中的研究现状[J].中国肿瘤临床与康复,2011,18(6):571-573. 被引量：5
-
5唐云章,邵小松,宫道华.儿童神经母细胞瘤临床分析[J].江苏医药,2002,28(8):636-636. 被引量：5
-
6张亦琳,朱建平,叶军.肝癌的治疗方法[J].健康博览,2010(11):12-13.
-
7蒋莲秀,赵一.常用治疗肝癌中药及作用机制研究进展[J].广西中医学院学报,2005,8(2):73-77. 被引量：14
-
8丁关庆.甲胎蛋白(AFP)与肝癌[J].中老年保健,1994(2):11-11.
-
9倪泉兴,杨峰.规范诊治,努力提高胰腺癌的远期生存率[J].中国普外基础与临床杂志,2006,13(5):493-495. 被引量：8
-
10童萱.胰腺癌手术成功率提高[J].特别健康,2015,0(11):27-27.
